Why is the Pro Medicus share price sinking on Monday?

What's going on with shares in the medical imaging company today?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Pro Medicus shares are down 7.2% to $44.06
  • The company's share price is being heavily weighed down by Wall Street's performance on Friday
  • Trading at an extremely high P/E ratio, investors have chosen to sell off Pro Medicus shares

The Pro Medicus Ltd (ASX: PME) share price is plummeting today despite no new announcements from the company.

At the time of writing, the health imaging company's shares are down a sizeable 7.2% to $44.06 after recovering from an intraday low of $43.05. That's 9.3% lower.

a concerned medical doctor examines an Xray from an imaging machine in a hospital setting.

Image source: Getty Images

What's dragging Pro Medicus shares lower?

A catalyst for the Pro Medicus share price falling deep in the red today has come from broader market weakness.

The S&P/ASX 200 Index (ASX: XJO) is tumbling 1.31% lower to 7,337 points following Wall Street's heavy losses last week.

In particular, the tech-focused Nasdaq fell 4.2% on Friday, registering its lowest closing levels in more than 12 months.

The selling pressure led to the index sinking 13.26% in April, its worst month since October 2008. This was brought on by an underwhelming performance from the tech titans such as Amazon, Netflix, and Meta Platforms.

While Pro Medicus is not directly related to the above companies, it does operate in the United States.

Furthermore, with an extremely high price-to-earnings (P/E) ratio of 118.95, this is bound to cause a jerk reaction.

Investors clearly are putting a lot of hope on Pro Medicus further expanding in North America. However, with the current market volatility, the company's shares are the first to be hit hard.

About the Pro Medicus share price

Over the last 12 months, the Pro Medicus share price has lost around 7% with year to date down 30%.

The company's shares reached a 2022 high of $63.12 on 4 January, before plunging 30% in the weeks following.

Since then, the company's shares have moved in circles.

Based on valuation grounds, Pro Medicus commands a market capitalisation of around $4.6 billion.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus Ltd. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »

A child covering his eyes hiding from a toy bear.
Healthcare Shares

Down 20% in 2026, is now the time to buy CSL shares?

CSL shares hit a new multi-year low as the 2026 decline deepens.

Read more »

Scientists in white coats look disappointed.
Healthcare Shares

Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?

The ASX healthcare share has plunged more than 87% in five trading days.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?

A potential cancer treatment is progressing.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

3 ASX healthcare stocks tipped to soar over 100% higher this year

These ASX shares are on my radar this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »

Wife and husband with a laptop on a sofa over the moon at good news.
Healthcare Shares

Why are Telix shares racing 8% higher today?

Telix shares are now 11% higher for the year-to-date.

Read more »